Novartis buys Kate Therapeutics, eyeing $55B CGT market opportunity by 2030

Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.